KR102785418B1 - 표적 단백질을 안정적으로 발현할 수 있는 재조합 바이러스 - Google Patents

표적 단백질을 안정적으로 발현할 수 있는 재조합 바이러스 Download PDF

Info

Publication number
KR102785418B1
KR102785418B1 KR1020207029714A KR20207029714A KR102785418B1 KR 102785418 B1 KR102785418 B1 KR 102785418B1 KR 1020207029714 A KR1020207029714 A KR 1020207029714A KR 20207029714 A KR20207029714 A KR 20207029714A KR 102785418 B1 KR102785418 B1 KR 102785418B1
Authority
KR
South Korea
Prior art keywords
gene
polynucleotide
recombinant virus
ehv
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207029714A
Other languages
English (en)
Korean (ko)
Other versions
KR20200135412A (ko
Inventor
광강 마
썬 유안
Original Assignee
베링거 잉겔하임 베트메디카 (차이나) 코포레이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 잉겔하임 베트메디카 (차이나) 코포레이션 리미티드 filed Critical 베링거 잉겔하임 베트메디카 (차이나) 코포레이션 리미티드
Publication of KR20200135412A publication Critical patent/KR20200135412A/ko
Application granted granted Critical
Publication of KR102785418B1 publication Critical patent/KR102785418B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207029714A 2018-03-19 2019-03-14 표적 단백질을 안정적으로 발현할 수 있는 재조합 바이러스 Active KR102785418B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018079410 2018-03-19
CNPCT/CN2018/079410 2018-03-19
PCT/CN2019/078057 WO2019179345A1 (en) 2018-03-19 2019-03-14 Recombinant virus capable of stably expressing target proteins

Publications (2)

Publication Number Publication Date
KR20200135412A KR20200135412A (ko) 2020-12-02
KR102785418B1 true KR102785418B1 (ko) 2025-03-26

Family

ID=67988104

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207029714A Active KR102785418B1 (ko) 2018-03-19 2019-03-14 표적 단백질을 안정적으로 발현할 수 있는 재조합 바이러스

Country Status (9)

Country Link
US (1) US11904010B2 (https=)
EP (1) EP3768831A4 (https=)
JP (1) JP7387623B2 (https=)
KR (1) KR102785418B1 (https=)
CN (1) CN111902535B (https=)
AU (1) AU2019237413C1 (https=)
CA (1) CA3094416A1 (https=)
MX (1) MX2020009720A (https=)
WO (1) WO2019179345A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3094416A1 (en) * 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica (China) Co., Ltd. Recombinant virus capable of stably expressing target proteins
CA3162622A1 (en) * 2019-11-25 2021-06-03 Baylor College Of Medicine Selective expansion of gene-targeted cells
CN112430625B (zh) * 2020-11-23 2022-08-05 武汉枢密脑科学技术有限公司 含有变异猪伪狂犬病病毒gD蛋白基因的重组腺相关病毒转移载体、病毒及其制备和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036651A1 (en) 1999-11-19 2001-05-25 Cantab Pharmaceuticals Research Limited Preparation of human or animal herpesviruses
CN101444622A (zh) * 2008-06-06 2009-06-03 中国人民解放军军事医学科学院军事兽医研究所 以猪伪狂犬病病毒为载体的日本血吸虫基因重组活疫苗生产工艺及制品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4110962A1 (de) * 1991-04-05 1992-10-08 Bayer Ag Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen
MX9206981A (es) * 1991-12-06 1994-08-31 Whitehead Biomedical Inst Vacunas de recombinantes y metodo para producirlas.
EP2468768A3 (en) * 2005-07-21 2012-10-31 Abbott Laboratories Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis
BRPI0618441B8 (pt) * 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
RU2546247C2 (ru) 2013-06-06 2015-04-10 Автономная некоммерческая организация "Научно-исследовательский институт диагностики и профилактики болезней человека и животных" (АНО "НИИ ДПБ") Вакцина против чумы, аденовирусных инфекций, парвовирусного и коронавирусного энтеритов, лептоспироза и бешенства собак
MA42640B1 (fr) * 2015-11-23 2021-06-30 Merial Inc Protéines de fusion de dmdv et e2 et leurs utilisations
CN107723281B (zh) 2017-09-09 2021-02-12 中国农业科学院哈尔滨兽医研究所 表达猪圆环病毒2型Cap蛋白的重组猪瘟兔化弱毒疫苗株及其应用
EA202092164A1 (ru) * 2018-03-19 2021-02-10 Бёрингер Ингельхайм Ветмедика Гмбх Новый ehv с инактивированным ul18 и/или ul8
CA3094416A1 (en) * 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica (China) Co., Ltd. Recombinant virus capable of stably expressing target proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036651A1 (en) 1999-11-19 2001-05-25 Cantab Pharmaceuticals Research Limited Preparation of human or animal herpesviruses
CN101444622A (zh) * 2008-06-06 2009-06-03 中国人民解放军军事医学科学院军事兽医研究所 以猪伪狂犬病病毒为载体的日本血吸虫基因重组活疫苗生产工艺及制品

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VETERINARY MEDICINE, 2016, vol. 63, pages 30-41.*
VETERINARY RESEARCH, 2013, vol. 44:48.*

Also Published As

Publication number Publication date
US11904010B2 (en) 2024-02-20
CN111902535A (zh) 2020-11-06
EP3768831A4 (en) 2022-01-05
MX2020009720A (es) 2021-01-08
AU2019237413B2 (en) 2025-08-07
AU2019237413A1 (en) 2020-09-24
US20210353734A1 (en) 2021-11-18
KR20200135412A (ko) 2020-12-02
CA3094416A1 (en) 2019-09-26
RU2020133457A (ru) 2022-04-19
CN111902535B (zh) 2024-08-27
WO2019179345A1 (en) 2019-09-26
EP3768831A1 (en) 2021-01-27
JP7387623B2 (ja) 2023-11-28
JP2021518152A (ja) 2021-08-02
AU2019237413C1 (en) 2025-10-30

Similar Documents

Publication Publication Date Title
US10905758B2 (en) Intranasal vector vaccine against porcine epidemic diarrhea
US10619169B2 (en) EHV insertion site ORF70
KR102785418B1 (ko) 표적 단백질을 안정적으로 발현할 수 있는 재조합 바이러스
US11261464B2 (en) Promoters
US11596681B2 (en) EHV insertion site UL43
JP2023012474A (ja) 不活性化ul18および/またはul8を有する新しいehv
RU2816428C2 (ru) Рекомбинантный вирус, способный к устойчивой экспрессии белков-мишеней
RU2816428C9 (ru) Рекомбинантный вирус, способный к устойчивой экспрессии белков-мишеней
EA046680B1 (ru) Новый ehv с инактивированным ul18 и/или ul8
EA048192B1 (ru) Новые промоторы
EA044953B1 (ru) Векторы аденовируса собачьих
EA046215B1 (ru) Новый ehv сайт инсерции orf70

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601